428 related articles for article (PubMed ID: 26078272)
1. H5N1 Vaccine-Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem.
Wheatley AK; Whittle JR; Lingwood D; Kanekiyo M; Yassine HM; Ma SS; Narpala SR; Prabhakaran MS; Matus-Nicodemos RA; Bailer RT; Nabel GJ; Graham BS; Ledgerwood JE; Koup RA; McDermott AB
J Immunol; 2015 Jul; 195(2):602-10. PubMed ID: 26078272
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages.
Whittle JR; Wheatley AK; Wu L; Lingwood D; Kanekiyo M; Ma SS; Narpala SR; Yassine HM; Frank GM; Yewdell JW; Ledgerwood JE; Wei CJ; McDermott AB; Graham BS; Koup RA; Nabel GJ
J Virol; 2014 Apr; 88(8):4047-57. PubMed ID: 24501410
[TBL] [Abstract][Full Text] [Related]
3. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.
Liu WC; Jan JT; Huang YJ; Chen TH; Wu SC
J Virol; 2016 Oct; 90(19):8496-508. PubMed ID: 27440889
[TBL] [Abstract][Full Text] [Related]
4. Conformational Stability of the Hemagglutinin of H5N1 Influenza A Viruses Influences Susceptibility to Broadly Neutralizing Stem Antibodies.
Wang W; Song HS; Keller PW; Alvarado-Facundo E; Vassell R; Weiss CD
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593038
[TBL] [Abstract][Full Text] [Related]
5. Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages.
Corbett KS; Moin SM; Yassine HM; Cagigi A; Kanekiyo M; Boyoglu-Barnum S; Myers SI; Tsybovsky Y; Wheatley AK; Schramm CA; Gillespie RA; Shi W; Wang L; Zhang Y; Andrews SF; Joyce MG; Crank MC; Douek DC; McDermott AB; Mascola JR; Graham BS; Boyington JC
mBio; 2019 Feb; 10(1):. PubMed ID: 30808695
[TBL] [Abstract][Full Text] [Related]
6. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans.
Ellebedy AH; Krammer F; Li GM; Miller MS; Chiu C; Wrammert J; Chang CY; Davis CW; McCausland M; Elbein R; Edupuganti S; Spearman P; Andrews SF; Wilson PC; García-Sastre A; Mulligan MJ; Mehta AK; Palese P; Ahmed R
Proc Natl Acad Sci U S A; 2014 Sep; 111(36):13133-8. PubMed ID: 25157133
[TBL] [Abstract][Full Text] [Related]
7. A unique and conserved neutralization epitope in H5N1 influenza viruses identified by an antibody against the A/Goose/Guangdong/1/96 hemagglutinin.
Zhu X; Guo YH; Jiang T; Wang YD; Chan KH; Li XF; Yu W; McBride R; Paulson JC; Yuen KY; Qin CF; Che XY; Wilson IA
J Virol; 2013 Dec; 87(23):12619-35. PubMed ID: 24049169
[TBL] [Abstract][Full Text] [Related]
8. A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses.
Hu H; Voss J; Zhang G; Buchy P; Zuo T; Wang L; Wang F; Zhou F; Wang G; Tsai C; Calder L; Gamblin SJ; Zhang L; Deubel V; Zhou B; Skehel JJ; Zhou P
J Virol; 2012 Mar; 86(6):2978-89. PubMed ID: 22238297
[TBL] [Abstract][Full Text] [Related]
9. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.
Throsby M; van den Brink E; Jongeneelen M; Poon LL; Alard P; Cornelissen L; Bakker A; Cox F; van Deventer E; Guan Y; Cinatl J; ter Meulen J; Lasters I; Carsetti R; Peiris M; de Kruif J; Goudsmit J
PLoS One; 2008; 3(12):e3942. PubMed ID: 19079604
[TBL] [Abstract][Full Text] [Related]
10. A human monoclonal antibody derived from a vaccinated volunteer recognizes heterosubtypically a novel epitope on the hemagglutinin globular head of H1 and H9 influenza A viruses.
Boonsathorn N; Panthong S; Koksunan S; Chittaganpitch M; Phuygun S; Waicharoen S; Prachasupap A; Sasaki T; Kubota-Koketsu R; Yasugi M; Ono K; Arai Y; Kurosu T; Sawanpanyalert P; Ikuta K; Watanabe Y
Biochem Biophys Res Commun; 2014 Sep; 452(3):865-70. PubMed ID: 25204499
[TBL] [Abstract][Full Text] [Related]
11. Monovalent H5 vaccine based on epitope-chimeric HA provides broad cross-clade protection against variant H5N1 viruses in mice.
He F; Prabakaran M; Rajesh Kumar S; Tan Y; Kwang J
Antiviral Res; 2014 May; 105():143-51. PubMed ID: 24637255
[TBL] [Abstract][Full Text] [Related]
12. Fully human broadly neutralizing monoclonal antibodies against influenza A viruses generated from the memory B cells of a 2009 pandemic H1N1 influenza vaccine recipient.
Hu W; Chen A; Miao Y; Xia S; Ling Z; Xu K; Wang T; Xu Y; Cui J; Wu H; Hu G; Tian L; Wang L; Shu Y; Ma X; Xu B; Zhang J; Lin X; Bian C; Sun B
Virology; 2013 Jan; 435(2):320-8. PubMed ID: 23084424
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing epitopes of influenza virus hemagglutinin: target for the development of a universal vaccine against H5N1 lineages.
Prabakaran M; He F; Meng T; Madhan S; Yunrui T; Jia Q; Kwang J
J Virol; 2010 Nov; 84(22):11822-30. PubMed ID: 20844051
[TBL] [Abstract][Full Text] [Related]
14. Influenza vaccination strategies targeting the hemagglutinin stem region.
Fukuyama H; Shinnakasu R; Kurosaki T
Immunol Rev; 2020 Jul; 296(1):132-141. PubMed ID: 32542739
[TBL] [Abstract][Full Text] [Related]
15. H1 Hemagglutinin Priming Provides Long-Lasting Heterosubtypic Immunity against H5N1 Challenge in the Mouse Model.
Carreño JM; Strohmeier S; Kirkpatrick Roubidoux E; Hai R; Palese P; Krammer F
mBio; 2020 Dec; 11(6):. PubMed ID: 33323511
[TBL] [Abstract][Full Text] [Related]
16. Two types of antibodies are induced by vaccination with A/California/2009 pdm virus: binding near the sialic acid-binding pocket and neutralizing both H1N1 and H5N1 viruses.
Ohshima N; Kubota-Koketsu R; Iba Y; Okuno Y; Kurosawa Y
PLoS One; 2014; 9(2):e87305. PubMed ID: 24505283
[TBL] [Abstract][Full Text] [Related]
17. A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection.
Du L; Zhao G; Sun S; Zhang X; Zhou X; Guo Y; Li Y; Zhou Y; Jiang S
PLoS One; 2013; 8(1):e53568. PubMed ID: 23320093
[TBL] [Abstract][Full Text] [Related]
18. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination.
Wei CJ; Boyington JC; McTamney PM; Kong WP; Pearce MB; Xu L; Andersen H; Rao S; Tumpey TM; Yang ZY; Nabel GJ
Science; 2010 Aug; 329(5995):1060-4. PubMed ID: 20647428
[TBL] [Abstract][Full Text] [Related]
19. The antigenic architecture of the hemagglutinin of influenza H5N1 viruses.
Velkov T; Ong C; Baker MA; Kim H; Li J; Nation RL; Huang JX; Cooper MA; Rockman S
Mol Immunol; 2013 Dec; 56(4):705-19. PubMed ID: 23933511
[TBL] [Abstract][Full Text] [Related]
20. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.
Moris P; van der Most R; Leroux-Roels I; Clement F; Dramé M; Hanon E; Leroux-Roels GG; Van Mechelen M
J Clin Immunol; 2011 Jun; 31(3):443-54. PubMed ID: 21174144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
